UGT1A1 (UDP glucuronosyltransferase family 1 member A1) is a phase II metabolizing enzyme that catalyzes the glucuronidation of endogenous compounds like bilirubin and exogenous substrates including drugs and environmental toxins 1. The enzyme primarily functions in the liver and gastrointestinal tract to facilitate detoxification and excretion of lipophilic compounds 2. UGT1A1 can form homodimers and heterodimers with other UGT1A isoforms, which modulates enzymatic activities in a substrate-dependent manner 3. Genetic polymorphisms in UGT1A1, particularly the *28 variant found in ~40% of Caucasians, significantly reduce enzyme expression and activity 14. These variants cause a spectrum of hyperbilirubinemia disorders, from mild Gilbert's syndrome to severe Crigler-Najjar syndrome 15. Clinically, UGT1A1 polymorphisms are critical for drug dosing, as reduced activity increases toxicity risk for substrates like irinotecan and belinostat 64. The enzyme also plays a role in metabolizing environmental toxins like dioxin, with polymorphisms affecting detoxification capacity 2. UGT1A1 expression and activity are elevated in response to toxic exposures, suggesting an adaptive detoxification response 2.